ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Clinical trials for ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE explained in plain language.
Never miss a new study
Get alerted when new ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE trials appear
Sign up with your email to follow new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered donor cells take on childhood leukemia in first human test
Disease control Recruiting nowThis early-stage trial tests a new type of cell therapy for children and young adults up to age 21 with a form of leukemia (CD19-positive) that has returned or not responded to treatment. The therapy uses immune cells from a family donor that are engineered in a lab to recognize …
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for tough blood cancers: venetoclax combo enters human trials
Disease control Recruiting nowThis early-phase trial is testing whether adding the drug venetoclax to standard chemotherapy is safe and tolerable for children, adolescents, and young adults with high-risk blood cancers like MDS, AML, and ALL. About 30 participants will receive different combinations of chemot…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: Andrew E. Place, MD • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New CAR t-cell combo aims to beat leukemia relapse
Disease control Recruiting nowThis study tests two approaches for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. One group gets a sequence of two types of CAR T-cells (targeting CD19 and CD22), while the other gets one type of CAR T-cell followed by a stem ce…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New CAR T-Cell therapy takes aim at tough T-Cell cancers
Disease control Recruiting nowThis study tests a new treatment called CD5 CAR T-cells for people with T-cell cancers (like certain leukemias) that have returned or not responded to standard care. The treatment uses a patient's own immune cells or cells from a donor, which are modified in a lab to recognize an…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Donor immune cells take on tough leukemia in early trial
Disease control Recruiting nowThis early-phase trial tests a two-step approach for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. First, patients receive donor-derived CD19 CAR T cells, then a stem cell transplant from the same donor, followed by donor-derive…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Can immune booster cells revive failing CAR-T therapy in leukemia?
Disease control Recruiting nowThis study tests whether adding cytokine-induced killer (CIK) cells can prevent CAR-T cells from wearing out too early in children and young adults with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia. About 213 participants will be randomly assigned to receive eith…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Engineered immune cells take on tough T-Cell cancers
Disease control Recruiting nowThis study tests a new treatment called CD7 CAR T-cell therapy for people with T-cell cancers that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells or cells from a donor, which are modified to find and attack cancer cells. The …
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Engineered immune cells take aim at tough T-Cell cancers
Disease control Recruiting nowThis study tests a new type of CAR T-cell therapy that targets a protein called CD5 on cancer cells. It is for people with T-cell cancers that have come back or not responded to standard treatments. The therapy uses the patient's own immune cells or cells from a donor, which are …
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Engineered immune cells take on Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase study tests a personalized therapy where a patient's own immune cells are modified to recognize and attack cancer cells. It is for children and adults with certain blood cancers (like leukemia or lymphoma) that have not responded to standard treatments. The goal …
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: Nelson Hamerschlak • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New combo therapy offers hope for kids with tough leukemia
Disease control Recruiting nowThis study tests a new combination of drugs for children and young adults whose leukemia or lymphoma has returned or not responded to treatment. The drugs include trametinib (a targeted therapy) plus standard chemotherapy. The goal is to find the safest dose and see if the combin…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: Princess Maxima Center for Pediatric Oncology • Aim: Disease control
Last updated Jun 26, 2026 18:46 UTC
-
New hope for kids with tough blood cancers: drug cocktail trial launches
Disease control Recruiting nowThis study tests a combination of two targeted drugs (ruxolitinib and venetoclax) plus standard chemotherapy in children and young adults up to age 21 whose leukemia or lymphoma has returned or not responded to treatment. The goal is to find the safest dose and see how many patie…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: Princess Maxima Center for Pediatric Oncology • Aim: Disease control
Last updated Jun 26, 2026 17:34 UTC